C4 Therapeutics, Inc. reported $35M of revenue over the trailing twelve months, +2.3% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $35M (to Q2 2026). Net income: −$101M, trailing twelve months to Q2 2026. Free cash flow: −$85M, trailing twelve months to Q2 2026. Operating margin: −342%, trailing twelve months to Q2 2026.

CCCCC4 Therapeutics, Inc.

Healthcare

$2.85+26% 1Y

$2.85

$1.7152 weeks$4.67

CCCC as reported

C4 Therapeutics, Inc. reported $35M of revenue over the trailing twelve months, +2.3% on the year before. 9 reported series are charted on this page, each one as filed.

$35M

Revenue, trailing twelve months · to Q2 2026 · +2.3% against the twelve months before

Net income: −$101M
Net income · −9.1% year on year · trailing twelve months to Q2 2026
Free cash flow: −$85M
Free cash flow · −2.5% year on year · trailing twelve months to Q2 2026
Operating margin: −342%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for CCCC, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$35M	+2.3%	Q2 2026
Net income	−$101M	−9.1%	Q2 2026
EPS	−$0.91	−42%	Q2 2026
Operating margin	−342%	n/a	Q2 2026
Net margin	−309%	n/a	Q2 2026
ROE	−51%	n/a	Q2 2026
ROA	−33%	n/a	Q2 2026
ROIC	−67%	n/a	Q4 2023 · 10 quarters behind
Free cash flow	−$85M	−2.5%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.